Photocure fundamentale forhold (PHO)

TekBot · februar 28, 2022, 6:32am

Photocure Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Press release - Oslo, Norway, 28 February 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the publication of new results from its
exploratory research program in the journal Biomedicines, entitled "Antitumor
…

Vis børsmeldingen

Effect and Induced Immune Response Following Exposure of Hexaminolevulinate
(HAL) and Blue Light in an Orthotopic Model of Rat Bladder Cancer". These
results support initial pre-clinical data on the potential anti-tumor effect of
HAL, which were presented at the BLADDR 2019 congress
[404: Not found
-the-bladdr-2019-congress-3457632].

The study objective was based on the hypothesis that the positive impact on long
-term outcomes in NMIBC patients who had undergone Blue Light Cystoscopy (BLC)
prior to cystectomy could be caused by a direct anti-tumor effect and/or
activation of the immune system indicating an additional effect of Blue Light
with HAL beyond pure detection. Therefore, as an exploratory preclinical study,
the authors investigated whether intravesical administration of HAL followed by
a diagnostic blue-light illumination-regime, aiming to mimic the one used
currently in Photodynamic Diagnosis (PDD), could have anti-tumor and/or immune
modulating effects as seen with Photodynamic therapy (PDT). In addition, it was
explored if co-administration of a checkpoint inhibitor would increase the
susceptibility to the PD-1/PD-L1 pathway inhibition thus increasing the anti
-tumor effect. Over the years, Photocure has conducted a number of experiments
on “mechanisms of actions” effects of HAL, as well as to see if there
potentially are similar anti-tumor and immune modulating effects of PDD with
blue light as reported with PDT. For this study, rats were treated with HAL and
blue light in an orthotopic model of bladder cancer, and then subjected to
histopathological analysis of the bladder samples and additional assessment of
immune markers. Co-administration of HAL and blue light with a checkpoint
inhibitor was further evaluated in this model aiming to assess for potentiation
of anti-tumor effects when combined with an immunotherapy.

Results of the study demonstrated an anti-tumor effect of HAL and blue light
when aiming to mimic the dosing regimen of a photodynamic diagnostic procedure
(PDD) in an orthotopic bladder cancer model in rats.

The authors conclude “The anti-tumor effect is most probably pertaining to
stimulation of the immune system as evident by tumor infiltration of CD3+ and
CD8+ T-cells. These results support our hypothesis that the positive impact on
patient outcomes observed in patients who had undergone BLC prior to cystectomy
could be explained by systemic immune activation induced by HAL and blue light.
Combination of HAL and blue light with intravesical anti-PD-L1 resulted in
increased anti-tumor effects. Further studies are warranted to explore the long
-term effects of HAL and blue light alone or in combination with checkpoint
inhibitors which should extend to investigate any systemic (abscopal) effects.
Intriguingly is also the idea that local treatment with HAL and blue light can
prime an immune response with potential additional effect of checkpoint
inhibitors.”

“The intriguing results from this pre-clinical study are encouraging and might
explain an effect of HAL+BL beyond pure detection. The results motivate further
research to evaluate the potential of HAL as a photodynamic therapy (PDT), which
may be an innovative technique for treatment of non-muscle invasive bladder
cancer.”, said Anders Neijber, Vice President, Global Medical Affairs and
Clinical Development at Photocure.

Read the full article here: Biomedicines | Free Full-Text | Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide, with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

Bonus · februar 28, 2022, 7:07am

Dette må jo være en meget hyggelig melding, det å kunne bevise att HAL har Anti-tumor effekt.

Dette har vel vært spekulert i tidligere, men nå ser det ut som det er bevist.

Dette vil utgjøre en enorm fordel for Photocure sin blærekreft satsing å kunne bevise att Hexvix har en Immune Response.

Oddbear · februar 28, 2022, 7:12am

Jeg ville vært litt forsiktig med å bruke utrykket “bevis”, men dette bør medføre at enhver blærekreftpasienter ønsker å la seg behandle med Cys/Hex.

Bonus · februar 28, 2022, 7:20am

Retter det til “probbaly”

Men én fantastisk nyhet er det jo.

The authors conclude “The anti-tumor effect is most probably pertaining to
stimulation of the immune system as evident by tumor infiltration of CD3+ and
CD8+ T-cells. These results support our hypothesis that the positive impact on
patient outcomes observed in patients who had undergone BLC prior to cystectomy
could be explained by systemic immune activation induced by HAL and blue light.
Combination of HAL and blue light with intravesical anti-PD-L1 resulted in
increased anti-tumor effects. Further studies are warranted to explore the long
-term effects of HAL and blue light alone or in combination with checkpoint
inhibitors which should extend to investigate any systemic (abscopal) effects.
Intriguingly is also the idea that local treatment with HAL and blue light can
prime an immune response with potential additional effect of checkpoint
inhibitors.”

Syvcys · februar 28, 2022, 7:52am

Jeg har selv sett dette forklart av en forskerkollega på en skjerm for ca 3 år siden, vedkommende prøvde å få til et samarbeid med pho uten å lykkes. Her var det tydelig at celler som hadde tatt opp cysview som ble bestrålt med blått lys døde fordi et livsnødvendig molekyl ble spaltet.

Tekspert · mars 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Savepig (109 likes)

@Rodjer (89 likes)

@gabster (74 likes)

Resten av topp 10:

@myk (64 likes)
@rosk82 (43 likes)
@CanonBoy (37 likes)
@OYV (33 likes)
@Quadruple (30 likes)
@Snoeffelen (24 likes)
@TyrionIV (23 likes)

Gratulerer!

TekBot · mars 4, 2022, 7:02am

Photocure announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Press release - Oslo, Norway, 4 March 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that it has entered into an exclusive
distribution agreement with Endotherapeutics Group for the commercialization of
…

Vis børsmeldingen

Hexvix[®] in Australia and New Zealand, and has terminated its distribution
agreement with Juno Pharmaceuticals (Juno). Under the new agreement,
Endotherapeutics will hold Marketing Authorizations and will re-launch Hexvix in
the two territories. All three parties will work closely together to ensure a
streamlined transfer and uninterrupted Hexvix supply to customers.

Endotherapeutics is a leading diversified medical technologies company focused
on improving healthcare in Australia and New Zealand for over 20 years across
several specialty areas. Its subsidiaries in Australia (Endotherapeutics Pty.
Ltd) and New Zealand (Endotherapeutics NZ Ltd, trading as Endoventure) will be
responsible for the commercialization of Hexvix in their respective territories.

Urology and men’s health represent important treatment segments for
Endotherapeutics, with a highly qualified and experienced urology team that is
customer focused and provides access to technologies and clinical support to the
private and public health care sectors. Endotherapeutics Pty. Ltd and
Endoventure are the exclusive distributors of the HIVECT bladder recirculation
system in Australia and New Zealand used in the treatment of bladder cancer*.
Endotherapeutics’ already established relationships with Urologists treating
bladder cancer offers clear synergies for the simultaneous promotion of Hexvix.

Photocure and Juno have mutually agreed to terminate their distribution
agreement dating back to 2015. Since in-licensing Hexvix, Juno’s business model
has evolved towards a focus on off-patent hospital tender products and away from
the regular sales, service and support required to market Hexvix. Photocure and
Juno will support Endotherapeutics to ensure a smooth transition and
uninterrupted supply of the product.

“We are pleased to enter into this agreement with Endotherapeutics to distribute
and market Hexvix in Australia and New Zealand. Their regional presence,
expertise and relationship with urologists is impressive. We are looking
forward to working with them to bring the benefits of BLC with Hexvix to
patients who suffer from bladder cancer,” said Dan Schneider, President and CEO
of Photocure.

“We look forward to adding Hexvix to our suite of products in urology care and
bringing it to more clinics and hospitals in Australia and New Zealand to
improve the quality of bladder cancer management. Our preliminary discussions
with top clinicians who treat bladder cancer confirm that there is a significant
need for Hexvix. It is a privilege to work with the Photocure team and the blue
light cystoscopy equipment providers to broaden the use of Hexvix in our
region,” said Ivan Srejber, Group Executive Chairman, Endotherapeutics Australia
and New Zealand.

*Photocure is the exclusive distributor for the HIVECT system in the Nordic
countries

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +47 45055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Endotherapeutics
Endotherapeutics was founded in 1999 by Ivan Srejber with a small team, with a
focus on innovative, specialised medical technologies that provided access to
life-improving solutions to healthcare professionals and their patients.

With its mission of “Improving Healthcare” and a strong focus on its values,
Endotherapeutics is proud of its strong reputation and relationships with
customers and partnering with leading international healthcare companies.

Over 20 years of experience has allowed Endotherapeutics to develop extensive
knowledge of the Australian and New Zealand healthcare systems. This includes
the registration and reimbursement of new medical technologies and their
successful sales and marketing.

Today Endotherapeutics is a leading Australian healthcare technologies company
that operates across both Australia and New Zealand. In New Zealand
Endotherapeutics is known and trades as Endoventure, and is a highly regarded
and customer focused organisation, whose Managing Director is Rachelle Hodgson.

Endotherapeutics contacts:
Ivan Srejber
Group Executive Chairman | Australia & New Zealand
Email: isrejber@endotherapeutics.com.au

New Zealand contact information:
Rachelle Hodgson
Managing Director
Endoventure
Email: Rachelle@endoventure.com

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [April 2021].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3] Sievert KD et al. World J Urol 2009;27:295-300

[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Canada, Chile, Australia and New Zealand. Please refer
to https://photocure.com/partnering-with-photocure/our-partners/ for further
information on our commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

Kilde

TekBot · mars 14, 2022, 12:03pm

Photocure ASA: Exercise of employee share options and share capital increase

Oslo, Norway, 14 March 2022: Participants in Photocure ASA’s (“Photocure” or the
“Company”) share option program have on 14 March 2022 exercised a total of 2,750
options distributed as follows:
…

Vis børsmeldingen

· 500 options exercised according to the option program for 2019 at a strike
price of NOK 50.72;
· 1,250 options exercised according to the option program for 2020 at a strike
price of NOK 81.41; and
· 1,000 options exercised according to the option program for 2020 at a strike
price of NOK 87.39.

Each option gives a right to receive one share in the Company. The share options
are described in note 7 and 23 in Photocure’s annual financial statements for
2020.

Following the exercise, the Board of Directors, pursuant to authorisation
granted by the Company’s Annual General Meeting, has decided to increase the
Company’s share capital by NOK 1,375 by issuing 2,750 new shares, of par value
NOK 0.50. Subsequent to the transaction, Photocure’s share capital will be NOK
13,488,285 divided into 26,976,570 shares, each share having a par value of NOK
0.50 and carrying one vote in the Company’s general meeting.

No primary insiders have exercised share options.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is subject to the disclosure requirements pursuant to the
market abuse regulation article 19 and 5-12 of the Norwegian Securities Trading
Act.

Kilde

TekBot · mars 16, 2022, 10:05am

Photocure ASA: Share capital increase registered

Oslo, Norway, 16 March 2022: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) published on 14 March 2022
regarding a share capital increase following the exercise of share options.
…

Vis børsmeldingen

The issuance of 2,750 new shares has been registered with the Norwegian Register
of Business Enterprises. Following registration, the share capital of Photocure
is NOK 13,488,285 divided into 26,976,570 shares, each share having a par value
of NOK 0.50 and carrying one vote in the Company’s general meeting.

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA:
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com. All trademarks mentioned
in this release are protected by law and are registered trademarks of Photocure
ASA. This information is subject to the disclosure requirements pursuant to
sections 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · mars 29, 2022, 3:01pm

Photocure to Participate in Two Investor Conferences in April: DNB Small & Medium Enterprises and Needham Healthcare

Press Release - Oslo, Norway, 29 March 2022, Photocure ASA (OSE: PHO), The
Bladder Cancer Company, announces that President and Chief Executive Officer,
Dan Schneider and Chief Financial Officer, Erik Dahl will present corporate
…

Vis børsmeldingen

overviews and host 1-on-1 meetings with investors at the DNB Small & Medium
Enterprises Conference on April 7, 2022, and the 21[st ]Annual Needham
Healthcare Conference being held virtually April 11-14, 2022.

For the Needham Healthcare Conference, Photocure’s presentation is scheduled to
take place April 14[th] at 8:00am ET (2:00pm CET) and can be accessed via the
following link: https://wsw.com/webcast/needham117/pho.ol/2531984
About the conferences:

· Now in its 18th year, the DNB Small & Medium Enterprises Conference 2022 is
a one-day conference that will include company presentations from various
sectors. Before the pandemic, more than 500 investors, company representatives
and other market participants from the Nordics, UK and Continental Europe
attended the conference.
· The 21st Annual Needham Virtual Healthcare Conference will feature leading
public and private companies in the Biotechnology, Specialty Pharmaceuticals,
Medical Technology, and Diagnostics sectors.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: ds@photocure.com

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: ed@photocure.com

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: david.moskowitz@photocure.com

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: geir.bjorlo@corpcom.no

Kilde

Tekspert · april 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (146 likes)

@Savepig (111 likes)

@gabster (75 likes)

Resten av topp 10:

@myk (58 likes)
@rosk82 (40 likes)
@Fornybar (31 likes)
@tooeasy891 (28 likes)
@kreinh (27 likes)
@Quadruple (26 likes)
@OYV (20 likes)

Gratulerer!

TekBot · april 6, 2022, 6:52pm

Photocure ASA: Annual Report 2021

Oslo, Norway, 6 April 2022: Photocure ASA today announces the publication of the
Annual Report 2021, included the ESG report for 2021.

…

Vis børsmeldingen

The Board of Directors of Photocure ASA has approved the annual accounts for
2021. The financial statements and annual report for the financial year 2021 are
together with the ESG report and auditor’s report attached to this notice. The
ESEF file for 2021 is also attached.

The documents are enclosed and also made available at the company’s website
under https://photocure.com/investors-hub/investors-events-and
-presentations (https://photocure.com/investor/reports-and-presentations/).

For further information, please contact:
Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA:
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com. All trademarks mentioned
in this release are protected by law and are registered trademarks of Photocure
ASA. This information is subject to the disclosure requirements pursuant to
sections 5-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · april 7, 2022, 11:05am

Photocure ASA - Notice of the annual general meeting 28 April 2022

Oslo, Norway, 7 April 2022: Photocure ASA (OSE: PHO), calls for the annual
general meeting of PHO to be held at Advokatfirmaet Selmer AS’ premises in
Tjuvholmen allé 1, 0252 Oslo, Norway on 28 April 2022 at 17:00 hours (CET).
…

Vis børsmeldingen

The notice convening the general meeting, including the agenda and the board’s
proposals to the matters to be dealt with, is enclosed with this notification
and will be sent to all shareholders with known addresses.

Relevant documents referred to in the notice are made available on
www.photocure.com.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000, Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

Savepig · april 9, 2022, 5:22pm

TekBot · april 26, 2022, 1:33pm

Photocure ASA: Final grant of conditional share options

Oslo, Norway, 26 April 2022: Reference is made to the stock exchange release by
Photocure ASA (“Photocure” or the “Company”) (OSE: PHO) published on 23 August
2021 regarding 607,500 share options granted conditionally.
…

Vis børsmeldingen

The board of directors in Photocure ASA has decided to convert a total of
607,500 conditional share options to unconditional share options.

Of the total share option conversion, the following unconditional share options
were converted for primary insiders:

· Dan Schneider, CEO, has received 135,000 share options, new total holding of
share options 295,000
· Erik Dahl, CFO, has received 67,500 share options, new total holding of
share options 122,500
· Geoffrey Coy, VP and General Manager North America, has received 67,500
share options, new total holding of share options 147,500
· Grete Hogstad, VP Global Strategic Marketing & Business Development, has
received 40,000 share options, new total holding of share options 77,500
· Patricia Kelly, VP Global Human Resources, has received 40,000 share
options, new total holding of share options 80,000
· Susanne Strauss, VP and General Manager Europe, has received 67,500 share
options, new total holding of share options 135,000

Primary insider notifications pursuant to the market abuse regulation article 19
are attached.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: +47 450 55 000
Email: ed@photocure.com

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

Kilde

kreinh · april 26, 2022, 2:41pm

“The board of directors in Photocure ASA has decided to convert a total of
607,500 conditional share options to unconditional share options”.

Hva gikk betingelsene ut på i forhold til betingningsløse aksje opsjoner?

Dreamliner · april 26, 2022, 6:59pm

Innløsningsprisen for disse opsjonene er kr. 145,27 per aksje. I note 7 i årsrapporten står det at opsjonene kan innløses over tre år med hhv 25%, 25% og 50% og at de faller bort etter fem år eller når noen slutter. Kan ikke se noen andre betingelser. Kan det bety at de nå kan innløse alle opsjonene i år 1 hvis f.eks. selskapet blir kjøpt opp?

kreinh · april 26, 2022, 7:26pm

Det er vel for å sikre administrasjonen greie fallskjermer ved oppkjøp tenker jeg…

Stovnerjonny · april 27, 2022, 6:15am

Nei, ikke hvis det ikke fremgår av betingelsene hvordan et oppkjøp påvirker opsjonsprogrammet. Uten det er det bare 25 % som gjelder. Hensikten er å gjøre det attraktivt å bli i selskapet. Ved oppkjøp kommer ofte nye avtaler på bordet…

TekBot · april 28, 2022, 3:55pm

Photocure ASA - Annual general meeting held

Oslo, Norway, 28 April 2022: Photocure ASA (OSE: PHO), held its annual general
meeting on 28 April 2022 at 17:00 hours (CET).

…

Vis børsmeldingen

All proposals were resolved as presented in the notice convening the annual
general meeting dated 7 April 2022, as further set out in the minutes from the
general meeting attached hereto.

For further information, please contact:

Photocure
CFO Erik Dahl
Tel: + 47 450 55 000
Email: ed@photocure.no

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, which makes
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com or www.cysview.com.

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde